✦ LIBER ✦

(273) Clinical trial results: A randomized, double-blind, placebo controlled, trial of three-day bupivacaine transdermal patch (ELADUR) in patients with post-herpetic neuralgia

✍ Scribed by M. Wallace; D. Kudrow; W. McElveen; M. Drass; L. Webster; J. Huddlestone; L. Reynolds; D. Lissin; P. Langecker

Book ID: 118475939
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 40 KB
Volume: 9
Category: Article
ISSN: 1528-8447
DOI: 10.1016/j.jpain.2008.01.194

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pregabalin reduces pain and improves sle

Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial

✍ Rainer Sabatowski; Rafael Gálvez; David A Cherry; Florence Jacquot; Emmanuelle V 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 180 KB

Efficacy and safety of milnacipran 100 m

Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: Results of a randomized, double-blind, placebo-controlled trial

✍ Lesley M. Arnold; R. Michael Gendreau; Robert H. Palmer; Judy F. Gendreau; Yong 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 248 KB 👁 2 views

Time to clinical remission in patients w

Time to clinical remission in patients with collagenous colitis treated with budesonide capsules-results of a randomized, double-blind, placebo-controlled trial

✍ Stephan Miehlke; Ahmed Madisch; Elke Bästlein; Eberhard Meier; Bernd Wigginghaus 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 26 KB

Febuxostat, a novel nonpurine selective

Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: A twenty-eight–day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout

✍ Michael A. Becker; H. Ralph Schumacher Jr.; Robert L. Wortmann; Patricia A. MacD 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 168 KB 👁 3 views

## Abstract ## Objective Gout affects ∼1–2% of the American population. Current options for treating hyperuricemia in chronic gout are limited. The purpose of this study was to assess the safety and efficacy of febuxostat, a nonpurine selective inhibitor of xanthine oxidase, in establishing normal

Safety Profile and Metabolic Effects of

Safety Profile and Metabolic Effects of 14 Days of Treatment with DIO-902: Results of a Phase IIa Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial in Patients with Type 2 Diabetes Mellitus

✍ Sherwyn L. Schwartz; Marc Rendell; Andrew J. Ahmann; Asha Thomas; Carlos J. Arau 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 118 KB